CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
15 déc. 2023 09h05 HE
|
Biogen Inc.
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...
U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
13 déc. 2023 14h03 HE
|
Spherix Global Insights
Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS)....
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
12 déc. 2023 07h00 HE
|
Athira Pharma, Inc.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
Global Medical Imaging Market Size to Reach USD 52.03 Billion in 2032 | Emergen Research
07 déc. 2023 09h10 HE
|
Emergen Research
Vancouver, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global medical imaging market, valued at USD 52.03 Billion in 2032, is set to experience substantial growth, with a projected revenue Compound Annual...
Contrast Media Market Size & Share to Surpass USD 7.8 billion by 2031 | Transparency Market Research, Inc.
06 déc. 2023 04h00 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The contrast media market is expected to reach US$ 7.8 billion by 2031 from US$ 4.9 billion...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
05 déc. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most...
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
04 déc. 2023 16h35 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
04 déc. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
- ATH434 improved motor performance and general function – - Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04,...
Global Stem Cells Market to surge at a CAGR of 11.6%, targeting an estimated value of USD 31,950 Million by 2030 as per Straits Research
30 nov. 2023 10h35 HE
|
Straits Research
New York, United States, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Recent advancements in stem cell therapies and tissue engineering have the potential to attract interest in the treatment of a variety of...
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
28 nov. 2023 04h00 HE
|
Harness Therapeutics
Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesisRefined focus on neurodegenerative...